Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 04/08/11 | Definitive proxy statements |
|
39 | ||
| 03/24/11 | SEC-generated letter |
|
1 | ||
| 03/23/11 | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
2 | ||
| 03/22/11 | SEC-generated letter |
|
2 | ||
| 03/15/11 | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | ||
| 03/15/11 | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
39 | ||
| 03/14/11 | Annual report pursuant to Section 13 and 15(d) |
|
66 | ||
| 03/03/11 | Current report filing |
|
9 | ||
| 01/05/11 | Statement of changes in beneficial ownership of securities |
|
1 | ||
| 01/05/11 | Statement of changes in beneficial ownership of securities |
|
2 |